Risk of Uncomplicated Peptic Ulcer in the General Population

AstraZeneca logo

AstraZeneca

Status

Completed

Conditions

Peptic Ulcer [Iowa Type (107680.0010)]

Treatments

Drug: Risk of symptomatic peptic ulcer

Study type

Observational

Funder types

Industry

Identifiers

NCT01888588
D5040N00006

Details and patient eligibility

About

The analyses are conducted in a previous population-based cohort study using The Health Improvement Network database in the UK (Cai et al 2009).The aims of the post hoc analyses are: To estimate the relative risk of uncomplicated symptomatic peptic ulcer (UPU) associated with use of low dose aspirin (ASA) and other anti-inflammatory drugs (NSAIDs, steroids) in the general population To estimate the dose-response and duration-response associated with use of these drugs To estimate the relative risk of UPU associated with naive/non-naive use of low dose ASA in the general population To evaluate the effect of proton pump inhibitors (PPI) (alone or in combination with anti-inflammatory drugs) on the occurrence of UPU in the general population To investigate the management of low dose ASA/oral antiplatelets after UPU

Full description

Risk of uncomplicated peptic ulcer in the general population

Enrollment

4,000 patients

Sex

All

Ages

40 to 84 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

- Patients aged 40-84 years in 1997-2005 ( see study population description)

Exclusion criteria

- Patients aged below age 40 and 85 years and above ( see study population description)

Trial design

4,000 participants in 2 patient groups

Cases
Description:
Patients with symptomatic peptic ulcer (UPU)
Treatment:
Drug: Risk of symptomatic peptic ulcer
Control group
Description:
Control group without symptomatic peptic ulcer (UPU).
Treatment:
Drug: Risk of symptomatic peptic ulcer

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems